• Cerenome unit CNSide signed an in-network ancillary provider agreement with Florida Blue, effective Oct. 1, 2026.
• Deal sets contracted reimbursement for CNSide CSF tumor cell enumeration, including new CSF Molecular Profile tests for CNS cancers.
• Florida Blue adds about 6 million covered lives, lifting contracted payer access to about 164 million commercial, Medicare Advantage lives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerenome Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080730PRIMZONEFULLFEED9841966) on October 08, 2026, and is solely responsible for the information contained therein.